Ownership and insider activity for HCW Biologics Inc. (HCWB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases.
Price
| Price | $2.01 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-29 | Wong Hing C | P-Purchase | 23,210 | $60K |
| 2026-07-29 | Flowers Lee | P-Purchase | 7,736 | $20K |
| 2026-07-29 | GARRETT SCOTT T | P-Purchase | 7,736 | $20K |
| 2026-05-22 | Wong Hing C | P-Purchase | 113,879 | $160K |
| 2026-05-22 | Wong Hing C | P-Purchase | 113,879 | $146K |
| 2026-05-22 | GARRETT SCOTT T | P-Purchase | 177,936 | $250K |
| 2026-05-22 | GARRETT SCOTT T | P-Purchase | 177,936 | $228K |
| 2026-05-22 | Byam Rebecca | P-Purchase | 14,235 | $20K |
| 2026-05-22 | Byam Rebecca | P-Purchase | 14,235 | $18K |
| 2025-05-16 | Wong Hing C | P-Purchase | 8,054 | $60K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.4M | $8.5M | $11.7M | $22.3M | $3.6M | $4.7M | $2.0M |
| Short-term Investments | 0 | 0 | $25.0M | $9.7M | 0 | 0 | 0 |
| Receivables | 0 | $2.5M | $133000 | $417695 | $1.5M | $582201 | $32175 |
| Inventory | 0 | 0 | 0 | $1.4M | 0 | 0 | 0 |
| Total Current Assets | $8.0M | $12.1M | $40.5M | $34.1M | $6.4M | $5.7M | $2.3M |
| Property, Plant & Equipment | $2.0M | $1.6M | $1.1M | $10.8M | $20.5M | $22.9M | $20.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $10.1M | $15.4M | $53.5M | $46.8M | $28.5M | $30.2M | $24.5M |
| Accounts Payable | $392331 | $155343 | $223664 | $1.2M | $6.2M | $22.3M | $13.1M |
| Short-term Debt | 0 | $567311 | 0 | 0 | 0 | $6.3M | $6.8M |
| Total Current Liabilities | $1.1M | $1.0M | $2.3M | $3.0M | $8.7M | $29.6M | $21.1M |
| Long-term Debt | 0 | 0 | 0 | $6.4M | $6.3M | $7.4M | 0 |
| Total Liabilities | $1.1M | $1.0M | $2.3M | $9.4M | $15.1M | $37.0M | $21.8M |
| Retained Earnings | -$9.7M | -$16.7M | -$30.6M | -$45.5M | -$70.5M | -$100.6M | -$108.5M |
| Total Equity | $9.0M | $14.4M | $51.2M | $37.4M | $13.5M | -$6.8M | $2.8M |
| Total Debt | 0 | $567311 | 0 | $6.4M | $6.3M | $13.7M | $6.8M |
| Net Debt | -$7.4M | -$7.9M | -$36.7M | -$25.7M | $2.7M | $9.0M | $4.9M |
| Working Capital | $7.0M | $11.1M | $38.2M | $31.1M | -$2.3M | -$23.9M | -$18.8M |
Financial Health
| Debt / Equity | 0.88 |
| Current Ratio | 0.06 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -8.57 |
Profitability
| Return on Equity | -142.16% |
| Return on Invested Capital | -39.28% |
| Return on Assets | -18.39% |
| Gross Margin | 95.91% |
| Operating Margin | -91.57% |
| Net Margin | -73.22% |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · BCLI · CELZ
Explore sector: Healthcare · Biotechnology
More sections of HCWB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks